免責聲明: 本站彙整 FDA、ClinicalTrials.gov、PubMed、SEC EDGAR 等官方公開資料，僅供一般參考，不構成醫療建議、診斷、治療建議或投資建議。

FDA 510(k)

BOND 即用型（RTU）主要抗體 孕酮受體（16），Novocastra濃縮液體小鼠單克隆抗體

K 號：K183102 · 2018-12-07

申請人Leica Biosystems Newcastle, Limited
決定日期2018-12-07
產品代碼MXZ
諮詢委員會HE 請提供完整的描述文本，以便我能夠進行翻譯。
決定相當於

器材摘要

BOND Ready-to-Use (RTU) Primary Antibody Progesterone Receptor (16) , Novocastra Concentrated Liquid Mouse Monoclonal Antibody is the device name listed in this FDA 510(k) record. The listed applicant is Leica Biosystems Newcastle, Limited. It received FDA 510(k) clearance on 2018-12-07 under 510(k) number K183102. The device is classified under product code MXZ. It was reviewed by the HE advisory panel. FDA Decision: Substantially Equivalent.

常見問題

What is the BOND Ready-to-Use (RTU) Primary Antibody Progesterone Receptor (16) , Novocastra Concentrated Liquid Mouse Monoclonal Antibody?

BOND Ready-to-Use (RTU) Primary Antibody Progesterone Receptor (16) , Novocastra Concentrated Liquid Mouse Monoclonal Antibody is a medical device that received FDA 510(k) clearance on 2018-12-07. The listed applicant is Leica Biosystems Newcastle, Limited. The 510(k) number is K183102.

When did BOND Ready-to-Use (RTU) Primary Antibody Progesterone Receptor (16) , Novocastra Concentrated Liquid Mouse Monoclonal Antibody receive FDA 510(k) clearance?

BOND Ready-to-Use (RTU) Primary Antibody Progesterone Receptor (16) , Novocastra Concentrated Liquid Mouse Monoclonal Antibody received FDA 510(k) clearance on 2018-12-07, under 510(k) number K183102.

Who is the listed applicant for BOND Ready-to-Use (RTU) Primary Antibody Progesterone Receptor (16) , Novocastra Concentrated Liquid Mouse Monoclonal Antibody?

The FDA 510(k) record lists Leica Biosystems Newcastle, Limited as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for BOND Ready-to-Use (RTU) Primary Antibody Progesterone Receptor (16) , Novocastra Concentrated Liquid Mouse Monoclonal Antibody?

The FDA product code for BOND Ready-to-Use (RTU) Primary Antibody Progesterone Receptor (16) , Novocastra Concentrated Liquid Mouse Monoclonal Antibody is MXZ.

相關臨床試驗

相關紀錄係使用名稱、產品代碼或其他後設資料自動配對。配對結果並不構成已驗證的臨床、科學、企業或監管關係，請查閱連結的官方來源。

NCT07608549FLASH 預試階段 1 安全性研究NOT_YET_RECRUITINGNCT06562205PAP系統外部臨床研究（ECS）NOT_YET_RECRUITINGNCT06443177對於動脈瘤性硬腦膜下出血引起的腦血管收縮，交感調節的影響SUSPENDEDNCT07095751人工智能協助的Uro-Cam導尿管評估系統，用於診斷膀胱癌NOT_YET_RECRUITING

其他以 Leica Biosystems Newcastle, Limited 為申請人之記錄

相關紀錄係使用名稱、產品代碼或其他後設資料自動配對。配對結果並不構成已驗證的臨床、科學、企業或監管關係，請查閱連結的官方來源。

K183100雌性激素受體克隆6F11即用型原體抗體，適用於Bond，雌性激素受體克隆6F11濃縮液體原體抗體，NovocastraK171753BOND 即用型（RTU）主要抗體 孕酮受體（16），Novocastra 液體小鼠單克隆抗體 孕酮受體克隆 16

相關器械（代碼：MXZ）

相關紀錄係使用名稱、產品代碼或其他後設資料自動配對。配對結果並不構成已驗證的臨床、科學、企業或監管關係，請查閱連結的官方來源。

K193393BOND 即用型主要抗體 孕酮受體 (16)，Novocastra 液體小鼠單克隆抗體 孕酮受體克隆 16（濃縮液體抗體格式）。Leica Biosystems Newcastle, Ltd.K170005FLEX 鼠單克隆抗人黃體激素受體，克隆號 PgR 1294，即用型（Dako Omnis）Dako Denmark A/SK171753BOND 即用型（RTU）主要抗體 孕酮受體（16），Novocastra 液體小鼠單克隆抗體 孕酮受體克隆 16Leica Biosystems Newcastle, LimitedK160922FLEX單克隆兔抗人雌激素受體a，克隆EP1，即用型（連結）；FLEX單克隆小鼠抗人孕酮受體，克隆PgR 636，即用型（連結）Dako North America, Inc.

官方來源

在 FDA 資料庫中查看 →

資料來源為 FDA Open API。如需最新且權威的資訊，請始終參閱官方記錄。

↑